Abstract:ID 92941 Poster Board 546 Ebola virus (EBOV), a negative-sense RNA virus, is zoonotic pathogen that causes severe hemorrhagic fever with high case fatality rates in humans. EBOV disease outbreaks have been occurring since 1976. The largest outbreaks took place in West African in 2014 and resulted in over 28,000 cases and 11,000 deaths. There have been advances in the development of EBOV vaccines and monoclonal antibodies. However, no antiviral drugs are yet approved, especially for the treatment of pan-filovirus infections. EBOV transcription requires viral VP30 and VP35 proteins, which, according to our recently conducted global proteomic study (1), are phosphorylated in the EBOV virions. Phosphorylation of VP35 on Thr-210 regulated EBOV transcriptional activity and VP35 interaction with EBOV-NP (1). Host protein phosphatases, PP1 and PP2A were shown to facilitate EBOV transcription and replication (2,3). Our unpublished observations indicate that NP E619K mutant binds stronger to PP1 and that binding compromises formation of EBOV capsid. Thus, targeting PP1 might be a valuable approach for EBOV inhibition. Recent high throughout screen conducted in Mathieu Bollen's laboratory at KULeuven identified several gold-containing compounds including FDA approved Auranofin among 400,000 compounds that were screened for PP1 as target. Here we tested the effect of Auranofin and chloro-gold compounds on EBOV transcription and replication and NP interaction with VP35. Auranofin inhibited EBOV minigenome (IC 50 = 0.5 μM) and also potently inhibited EBOV and MARV replication in Vero E6 cells at submicromolar concentrations. Compared to chloro-gold compound, Auranofin showed at least 10-times better efficacy and also less toxicity. To determine the mechanism of Auranofin action, we investigated its effect on the NP-VP35 and NP-NP interactions using split NanoBiT assay. Auranofin potently inhibited NP binding to VP35 in split NanoBiT (IC 50 = 3 μM) comparing to chloro-gold (IC 50 = 12 μM). Auranofin demonstrated low cytotoxicity (IC 50 >300 μM) in 293T cells that were used for the split NanoBiT. Auranofin also showed potent inhibition of NP-NP interaction in split NanoBiT (IC 50 = 1 μM) comparing to chloro-gold (IC 50 = 3 μM). Taken together, our study suggests that Auranofin may serve as EBOV inhibitor by targeting EBOV NP-VP35 and NP-NP interactions. As Auranofin is approved for human use for rheumatoid arthritis, it is feasibly can be further tested as an inhibitor for EBOV and MARV infections References Ivanov A, ... Bukreyev A, Nekhai S. 2020. Global phosphoproteomic analysis of Ebola virions reveals a novel role for VP35 phosphorylation-dependent regulation of genome transcription. Cell Mol Life Sci 77:2579–2603. Ilinykh PA, ... Nekhai S, Bukreyev A. 2014. Role of protein phosphatase 1 in dephosphorylation of Ebola virus VP30 protein and its targeting for the inhibition of viral transcription. J Biol Chem 289:22723–38. Kruse T, ... Nilsson J, Becker S. 2018. The Ebola Virus Nucleoprotein Recruits the Host PP2A-B56 Phosphatase to Activate Transcriptional Support Activity of VP30. Mol Cell 69:136–145 e6 Acknowledgements: We thank Dr. Mathieu Bollen for sharing screening data, Dr. Elke Mühlberger for providing the EBOV minigenome, and Dr. Yoshihiro Kawaoka for providing the plasmids expressing EBOV NP, VP35, L, VP30, and the T7 polymerase. This project was supported by the NIH Research Grants U19AI109664, 5U54MD007597, 2R01HL125005 and P30AI117970

Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs

High-Throughput Screening of an FDA-Approved Drug Library Identifies Inhibitors against Arenaviruses and SARS-CoV-2

The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses

Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors

Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library

Repurposing potential of 1st generation H1-specific antihistamines as anti-filovirus therapeutics

A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus

Arbidol: The current demand, strategies, and antiviral mechanisms

Repurposing of berbamine hydrochloride to inhibit Ebola virus by targeting viral glycoprotein

Comparison of Routes of Administration, Frequency, and Duration of Favipiravir Treatment in Mouse and Guinea Pig Models of Ebola Virus Disease

High-Throughput Screening of FDA-Approved Drug Library Reveals Ixazomib is a Broad-Spectrum Antiviral Agent Against Arboviruses.

Small-Molecule Probes Targeting the Viral Ppxy-Host Nedd4 Interface Block Egress of A Broad Range of Rna Viruses

Identification of Clotrimazole Derivatives as Specific Inhibitors of Arenavirus Fusion

Recombinant Pichinde reporter virus as a safe and suitable surrogate for high-throughput antiviral screening against highly pathogenic arenaviruses

Design, Synthesis and Anti-HIV-1 Evaluation of Novel Arylazolylthioacetanilides As Potent NNRTIS

Repurposed antibiotic and antiviral drugs inhibit the immune evasive endoribonuclease of SARS-CoV-2 and restrict coronavirus infection in vitro

N 4 -Hydroxycytidine/molnupiravir inhibits RNA virus-induced encephalitis by producing less fit mutated viruses

An orally active entry inhibitor of influenza A viruses protects mice and synergizes with oseltamivir and baloxavir marboxil

Lactic acid bacterial surface display of scytovirin inhibitors for anti-ebolavirus infection

Auranofin Inhibits Ebola Virus Replication by Targeting NP-VP35 and NP-NP Interactions

Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform